Glaukos Announces Participation in Stephens Investor Conference
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Oct 30, 2019--
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stephens Investor Conference on Wednesday, November 13, 2019, at 2:30 p.m. CST in Nashville, TN.
A live audio webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com and will be archived for 90 days.
Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191030005752/en/
CONTACT: Chris Lewis
Director, Investor Relations, Corporate Strategy & Development
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL OPTICAL HEALTH
SOURCE: Glaukos Corporation
Copyright Business Wire 2019.
PUB: 10/30/2019 04:15 PM/DISC: 10/30/2019 04:15 PM